- active not recruitingPHASE3
Pegcetacoplan Long Term Safety and Efficacy Extension Study
This study is for people with PNH who have already been in a pegcetacoplan trial. It looks at the long-term safety and how well the treatment works over time. Participants will continue to receive pegcetacoplan.
United States · Australia · Belgium - recruitingPHASE3
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
This study looks at a new add-on medicine, danicopan, for young people (12-17 years old) with a rare blood condition called PNH. It aims to see if danicopan can improve red blood cell levels when added to their current treatment.
Canada · France · United Kingdom